Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant. Materials and methods: This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed. Results: A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected. Conclusion: We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.
Abstract
Purpose: Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant. Materials and methods: This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed. Results: A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected. Conclusion: We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.
참고문헌 (26)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
- Miki Y, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, 266, pp.66~71 (1994)
- Wooster R, "Identification of the breast cancer susceptibility gene BRCA2", Nature, 378, pp.789~792 (1995)
- Choi DH, "Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients", J Clin Oncol, 22, pp.1638~1645 (2004)
- Han SH, "Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer", Clin Genet, 70, pp.496~501 (2006)
- Ahn SH, "BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations", Cancer Lett, 245, pp.90~95 (2007)
- Atchley DP, "Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer", J Clin Oncol, 26, pp.4282~4288 (2008)
- Copson ER, "Germline BRCA mutation and outcome in young-onset breast cancer(POSH) : a prospective cohort study", Lancet Oncol, 19, pp.169~180 (2018)
- Veronesi A, "Familial breast cancer : characteristics and outcome of BRCA 1-2 positive and negative cases", BMC Cancer, 5, pp.70~ (2005)
- Musolino A, "BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer : a population-based study", Breast, 16, pp.280~292 (2007)
- Atci MM, "Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles : a retrospective study", Eur J Breast Health, 17, pp.123~127 (2021)
- Lavie O, "Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population", Ann Oncol, 22, pp.964~966 (2011)
- Leegte B, "Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations", J Med Genet, 42, pp.e20~ (2005)
- Smith M, "Familial breast cancer : double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes", Fam Cancer, 7, pp.119~124 (2008)
- Rebbeck TR, "Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32, 295 women", Breast Cancer Res, 18, pp.112~ (2016)
- Heidemann S, "Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients : implications on test strategies and clinical management", Breast Cancer Res Treat, 134, pp.1229~1239 (2012)
- Noh JM, "Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients", Breast Cancer Res Treat, 131, pp.217~222 (2012)
- Musolino A, "A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes", Breast Cancer Res Treat, 91, pp.203~205 (2005)
- Bayraktar S, "BRCA mutation genetic testing implications in the United States", Breast, 31, pp.224~232 (2017)
- Nomizu T, "A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes", Breast Cancer, 22, pp.557~561 (2015)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Rennert G, "Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations", N Engl J Med, 357, pp.115~123 (2007)
- Kang E, "The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population : recent update of the Korean Hereditary Breast Cancer(KOHBRA)study", Breast Cancer Res Treat, 151, pp.157~168 (2015)
- Ryu JM, "Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from ‘unknown significance’ to ‘Likely pathogenic’ based on clinical evidence in Korea", Breast, 33, pp.109~116 (2017)
- "Fanconi anemia. Gene Reviews" (2018)[URL]
- Ramus SJ, "A breast", ovarian cancer patient with germline mutations in both BRCA1 and BRCA2, 1997, pp.15, 14~15